Tatva Chintan Pharma Chem Ltd (TATVA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543321 | NSE: TATVA | Chemicals | Small Cap

Tatva Chintan Pharma Share Price

1,387.30 -31.20 -2.20%
as on 05-Dec'25 15:23

Tatva Chintan Pharma Chem Ltd (TATVA) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543321 | NSE: TATVA | Chemicals | Small Cap

DeciZen - make an informed investing decision on Tatva Chintan Pharma

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Tatva Chintan Pharma Chem stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
236.94
Market Cap:
3,318.2 Cr.
52-wk low:
610
52-wk high:
1,603.6

Is Tatva Chintan Pharma Chem Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Tatva Chintan Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Tatva Chintan Pharma Chem Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 27.4%39%20.4%22.2%26.8%27.9%25.8%7.5%6.9%0.3%-
Value Creation
Index
1.01.80.50.60.91.00.8-0.5-0.5-1.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 89.9109129203254291428403379366417
Sales YoY Gr.-21%19%56.8%25.1%14.7%46.9%-5.8%-6%-3.2%-
Adj EPS 3.685.110.317.724.141.620.211.5-0.66
YoY Gr.-120.9%-36.4%101.2%72.8%35.7%72.8%-51.4%-43.4%-105.2%-
BVPS (₹) 16.124.730.239.65780.6211.5227.7310.3308.4313.3
Adj Net
Profit
7.316.110.320.635.648.392.144.826.8-1.414
Cash Flow from Ops. 8.724.312.97.924.618.919.823.710323.9-
Debt/CF from Ops. 2.41.94.49.83.74.86.17.20.11.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 16.9%7.6%-5%-3.2%
Adj EPS -181.7%-150.6%-124.2%-105.2%
BVPS38.8%40.2%13.4%-0.6%
Share Price - - -15% 55.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
25.439.318.629.436.73529.29.24.4-0.21.9
Op. Profit
Mgn %
16.523.715.917.121.122.524.814.317.77.111.9
Net Profit
Mgn %
8.114.87.910.21416.621.511.17.1-0.43.4
Debt to
Equity
0.70.90.910.80.60.30.300.10
Working Cap
Days
178175189152156190199251256247110
Cash Conv.
Cycle
475476728510611716717516556

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Tatva Chintan Pharma Chem Ltd.

Standalone Consolidated
TTM EPS (₹) 6 7.6
TTM Sales (₹ Cr.) 417 434
BVPS (₹.) 313.3 322.5
Reserves (₹ Cr.) 710 731
P/BV 4.53 4.40
PE 236.94 187.09
From the Market
52 Week Low / High (₹) 610.00 / 1603.60
All Time Low / High (₹) 610.00 / 2975.55
Market Cap (₹ Cr.) 3,318
Equity (₹ Cr.) 23.4
Face Value (₹) 10
Industry PE 48.1

Management X-Ray of Tatva Chintan Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Tatva Chintan Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Tatva Chintan Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales90109129203254291428403379366
Operating Expenses 7583109170201226322348312340
Manufacturing Costs5141520333665546765
Material Costs485268115130148196222168198
Employee Cost 761016212431415553
Other Costs 15111618181730302224
Operating Profit 152621335365106556726
Operating Profit Margin (%) 16.5%23.7%15.9%16.4%20.8%22.5%24.8%13.6%17.7%7.1%
Other Income 15501511684
Interest 2234445971
Depreciation 2244578102628
Exceptional Items 0001000-400
Profit Before Tax 12271826445910339420
Tax 41066987-2130
Profit After Tax 717122035519640290
PAT Margin (%) 8.3%15.9%9.2%9.9%13.8%17.6%22.4%10.0%7.8%0.1%
Adjusted EPS (₹)3.78.65.910.117.425.643.318.312.60.1
Dividend Payout Ratio (%)0%0%0%0%0%20%5%11%16%715%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 32506180114162469505726721
Share Capital 888882022222323
Reserves 24415372106142447483702698
Minority Interest0000000000
Debt2146567179761061601136
Long Term Debt4172032392713410
Short Term Debt172936404049921561036
Trade Payables15182422314744324432
Others Liabilities 39514203549442221
Total Liabilities 71123146187245320667740803811

Fixed Assets

Gross Block22227073122139186232488617
Accumulated Depreciation810137111827366189
Net Fixed Assets 14135667111120160196427529
CWIP 527106510512317724
Investments 11211111111
Inventories182024315968161151144123
Trade Receivables20293645519062906876
Cash Equivalents 418816104175393712
Others Assets 1015102392759334046
Total Assets 71123146187245320667740803811

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 9241382519202410324
PBT 12271826445910339420
Adjustment 32-078710162828
Changes in Working Capital -160-20-20-38-75-2339-0
Tax Paid -4-10-5-6-7-10-18-8-6-4
Cash Flow From Investing Activity -8-25-24-17-40-21-197-101-121-65
Capex -7-25-24-10-48-21-89-203-128-76
Net Investments 000-770-11297510
Others -11-00105530
Cash Flow From Financing Activity 11511710-5235383117
Net Proceeds from Shares 00000021101970
Net Proceeds from Borrowing 0001313-9-13-13-9-3
Interest Paid 0-0-3-4-4-4-5-8-7-1
Dividend Paid 00000-40-4-5-5
Others 115481134264-14626
Net Cash Flow 115-108-6-658-4013-25

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)25.8642.2521.6128.7636.0337.1630.438.314.770.05
ROCE (%)27.4238.9820.4322.1926.7827.8825.797.496.910.26
Asset Turnover Ratio1.431.20.961.221.171.030.870.570.490.45
PAT to CFO Conversion(x)1.291.411.080.40.710.370.210.63.55N/A
Working Capital Days
Receivable Days83769172698865687672
Inventory Days58616350658098141142133
Payable Days13111811473759685628271

Tatva Chintan Pharma Chem Ltd Stock News

Tatva Chintan Pharma Chem Ltd FAQs

The current trading price of Tatva Chintan Pharma on 05-Dec-2025 15:23 is ₹1,387.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Tatva Chintan Pharma stood at ₹3,318.2.
The latest P/E ratio of Tatva Chintan Pharma as of 04-Dec-2025 is 236.9.
The latest P/B ratio of Tatva Chintan Pharma as of 04-Dec-2025 is 4.53.
The 52-week high of Tatva Chintan Pharma is ₹1,603.6 and the 52-week low is ₹610.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tatva Chintan Pharma is ₹416.7 ( Cr.) .

About Tatva Chintan Pharma Chem Ltd

The company is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, it focuses on application of its products which form a key ingredient to its customers’ manufacturing and industrial processes. For instance, its SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.

The company continuously strive to improve its processes and infrastructure to help reduce its impact on the environment and have accordingly, undertaken various ‘green’ chemistry processes such as electrolysis. Considering the wide application of its products, it serve customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from company’s customers in India, it also export its products to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.

Business area of the company

The company is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals.

Awards, accreditations or recognitions

  • 2006: Received ISO 9001:2015 certification for manufacturing facility at Ankleshwar.
  • 2015: Appreciation certificate from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for Company’s contribution to the revenue and voluntary compliance with tax laws.
  • 2016: Accorded the status of a two star export house from the Directorate General of Foreign Trade, Ministry of Commerce and Industry, Government of India.
  • 2017: Received ISO 14001:2015 and BS OHSAS 18001:2007 certification for our manufacturing facility at Ankleshwar.
  • 2018: Received ISO 9001: 2015 certification for manufacturing facilities at Ankleshwar and Dahej.
  • 2018: Received ISO 14001: 2015 and BS OHSAS 18001:2007 certification for manufacturing facility at Dahej.
  • 2019: R&D facility recognized by the Department of Scientific and Industrial Research, Government of India for the purpose of availing customs duty exemption.
  • 2020: Received ISO 14001:2015 and 45001:2018 certification for manufacturing facility at Ankleshwar.

Major events and milestones

  • 1996: Incorporation of the company.
  • 2004: Received licence to manufacture for sale (or for distribution) of certain drugs from the Food and Drugs Control Administration, Gujarat at our Ankleshwar Manufacturing Facility.
  • 2007: Expansion of manufacturing capacity at Ankleshwar Manufacturing Facility.
  • 2011: Commenced commercial manufacturing of SDAs.
  • 2013: Attained turnover of Rs 500.00 million.
  • 2015: Attained turnover of Rs 1 billion.
  • 2015: Incorporation of Tatva Chintan USA Inc., a wholly owned Subsidiary of Company.
  • 2015: Set up warehousing facility in Netherlands.
  • 2017: Set up Dahej Manufacturing Facility.
  • 2018: Set up R&D facility in Vadodara.
  • 2019: Incorporation of Tatva Chintan Europe BV, a wholly owned Subsidiary of Company.
  • 2020: Completion of ‘Together for Sustainability’ audit.
  • 2020: Conversion of Ankleshwar Manufacturing Facility to a ‘zero liquid effluent discharge facility’.
  • 2020: Attained total revenue of Rs 2 billion.
  • 2020: Increase in manufacturing capacity at our Dahej Manufacturing Facility resulting in an increase in the aggregate manufacturing capacity of our Company from 160 KL and 10 Assembly Lines to 280 KL and 13 Assembly Lines.


To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×